siCoV/KK46

N/A

Report date: 2026/03/26 20:00:17
NME

Base Information

Drug NamesiCoV/KK46
Drug Alias NamesiCoV/KK46
ClassificationSmall molecules > Synthetic peptideSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesInstitute of Immunology Federal Medical-Biological AgencySt. Petersburg Scientific Research Institute of Vaccines and Sera
China Registration ClassN/A

Develop Information

Active CompaniesSt. Petersburg Scientific Research Institute of Vaccines and Sera
Inactive CompaniesInstitute of Immunology Federal Medical-Biological Agency
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A